A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

NCT ID: NCT05571943

Last Updated: 2024-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

542 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-15

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD. The study will also evaluate the long-term efficacy of difamilast ointment 1%, including durability of response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Difamilast Ointment 1%

A thin layer of Difamilast applied to affected areas twice daily (morning and evening, approximately 12 hours apart)

Group Type EXPERIMENTAL

Difamilast

Intervention Type DRUG

Difamilast Ointment 1%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Difamilast

Difamilast Ointment 1%

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects who are male or female ≥2 years of age at Screening (Visit 1).
2. Subjects who have a diagnosis of AD based on the American Academy of Dermatology AD diagnostic criteria
3. Subjects who have had a diagnosis of AD for at least 3 months prior to Screening .
4. Subjects who have an IGA of mild or moderate AD Severity and treatable body surface area (BSA) ≥3%at Baseline if not previously enrolled in study MEDI-MM36-301 OR b. IGA ≤ 3, with no minimum BSA and completed through Week 4/EOT Visit 6 of the study MEDI-MM36-301.
5. Subject is willing and able to comply with all study-related procedures, including, but not limited to, application of the study drug, and visit requirements.

Exclusion Criteria

1. Subjects who have an AD flare (defined as rapid intensification of AD) within 28 days prior to Screening or Baseline (except for those previously enrolled in Study MEDI-MM36-301) or history of consistent requirement for high-potency topical corticosteroids to manage AD signs and symptoms.
2. Subjects who have an active or acute skin infection (eg, herpes simplex, herpes zoster, or chicken pox), and/or clinically infected AD
3. Subjects with significant systemic or localized infection
4. Subjects with minimal/mild depression and suicidal ideation
5. Subjects using restricted medications, biologics and alternative therapies, or using investigational drug

\-
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acrotech Biopharma Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Uma S Atmuri, MPharm MS

Role: STUDY_DIRECTOR

Acrotech Biopharma Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Qualmedica Research, LLC

Birmingham, Alabama, United States

Site Status

AllerVie Health

Birmingham, Alabama, United States

Site Status

Elite Clinical Studies, LLC

Phoenix, Arizona, United States

Site Status

NEA Baptist Clinic-Dermatology

Jonesboro, Arkansas, United States

Site Status

First OC Dermatology

Fountain Valley, California, United States

Site Status

Center for Dermatology Clinical Research, Inc.

Fremont, California, United States

Site Status

Southern CA Dermatology Skin and Laser

Laguna Niguel, California, United States

Site Status

Antelope Valley Clinical Trials

Lancaster, California, United States

Site Status

Dermatology Research Associates

Los Angeles, California, United States

Site Status

Clinical Trials Research Institute

Thousand Oaks, California, United States

Site Status

Clarity Dermatology, LLC

Castle Rock, Colorado, United States

Site Status

IMMUNOe Research Centers

Centennial, Colorado, United States

Site Status

TrueBlue Clinical Research

Brandon, Florida, United States

Site Status

Annexus Dermatology & Aethestics

DeLand, Florida, United States

Site Status

Accel Research - Edgewater Clinical Research Unit

Edgewater, Florida, United States

Site Status

Skin Care Research

Hollywood, Florida, United States

Site Status

Kirsch Dermatology

Naples, Florida, United States

Site Status

Tory Sullivan, MD PA

North Miami Beach, Florida, United States

Site Status

Pure Skin Dermatology & Aesthetics

Orlando, Florida, United States

Site Status

Nona Pediatrics

Orlando, Florida, United States

Site Status

Accel Research - Ormond Clinical Research Unit

Ormond Beach, Florida, United States

Site Status

Olympian Clinical Research

St. Petersburg, Florida, United States

Site Status

Solaris Clinical Research

Meridian, Idaho, United States

Site Status

Arlington Dermatology

Rolling Meadows, Illinois, United States

Site Status

DS Research

Clarksville, Indiana, United States

Site Status

Qualmedica Research, LLC

Evansville, Indiana, United States

Site Status

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States

Site Status

The Indiana Clinical Trials Center

Plainfield, Indiana, United States

Site Status

South Bend Clinic

South Bend, Indiana, United States

Site Status

Options Research Group, LLC

West Lafayette, Indiana, United States

Site Status

Meridian Clinical Research

Overland Park, Kansas, United States

Site Status

Qualmedica Research, LLC

Bowling Green, Kentucky, United States

Site Status

DS Research

Louisville, Kentucky, United States

Site Status

Clinical Trials Management, LLC

Covington, Louisiana, United States

Site Status

Avant Research Associates, LLC

Crowley, Louisiana, United States

Site Status

Clinical Trials Management, LLC

Metairie, Louisiana, United States

Site Status

DermAssociates, LLC

Rockville, Maryland, United States

Site Status

Metro Boston Clinical Partners

Brighton, Massachusetts, United States

Site Status

Oakland Hills Dermatology, PC

Auburn Hills, Michigan, United States

Site Status

Michigan Dermatology Institute

Waterford, Michigan, United States

Site Status

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Site Status

Cleaver Dermatology

Kirksville, Missouri, United States

Site Status

Vivida Dermatology

Las Vegas, Nevada, United States

Site Status

Forest Hills Dermatology Group

Kew Gardens, New York, United States

Site Status

Bexley Dermatology Research

Bexley, Ohio, United States

Site Status

Optima Research

Boardman, Ohio, United States

Site Status

Remington-Davis, Inc.

Columbus, Ohio, United States

Site Status

Optimed Research

Columbus, Ohio, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Dermatology Associates of Plymouth Meeting

Plymouth Meeting, Pennsylvania, United States

Site Status

Peak Research, LLC

Upper Saint Clair, Pennsylvania, United States

Site Status

Palmetto Clinical Trial Services, LLC

Anderson, South Carolina, United States

Site Status

Coastal Pediatric Research

Charleston, South Carolina, United States

Site Status

International Clinical Research - Tennessee, LLC

Murfreesboro, Tennessee, United States

Site Status

Arlington Research Center, Inc.

Arlington, Texas, United States

Site Status

Derm Research

Austin, Texas, United States

Site Status

J&S Studies

College Station, Texas, United States

Site Status

North Texas Center for Clinical Research

Frisco, Texas, United States

Site Status

Center for Clinical Studies, Ltd, LLP

Houston, Texas, United States

Site Status

Research Your Health

Plano, Texas, United States

Site Status

Houston Center for Clinical Research

Sugar Land, Texas, United States

Site Status

Center for Clinical Studies

Webster, Texas, United States

Site Status

Premier Clinical Research, LLC

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MM36-302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.